Certolizumab pegol in rheumatoid arthritis: current update
| العنوان: | Certolizumab pegol in rheumatoid arthritis: current update |
|---|---|
| المؤلفون: | Yuzaiful Md Yusof, Paul Emery, Marie Fechtenbaum |
| المصدر: | Expert Opinion on Biological Therapy. 14:841-850 |
| بيانات النشر: | Informa Healthcare, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Clinical Biochemistry, Disease, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Certolizumab, Polyethylene Glycols, Arthritis, Rheumatoid, Disease activity, Immunoglobulin Fab Fragments, Internal medicine, Drug Discovery, medicine, Animals, Humans, Clinical efficacy, Certolizumab pegol, Pharmacology, Tumor Necrosis Factor-alpha, business.industry, medicine.disease, Safety profile, Treatment Outcome, Antirheumatic Agents, Expert opinion, Rheumatoid arthritis, Certolizumab Pegol, Physical therapy, Drug Therapy, Combination, business, medicine.drug |
| الوصف: | The development of TNF-α inhibitors (TNF-is) represents a major advancement in the treatment of rheumatoid arthritis (RA). Currently, there are five agents licensed for moderate-to-severely active RA. Certolizumab pegol (CZP) is a novel PEGylated, constant fragment-free TNF-i therapy, which is the focus of this review.Data from Phase III randomised controlled trials in terms of clinical efficacy, radiographic progression, patient-reported outcomes and safety profile are reviewed. These include long-term data from open-label extension studies.The advantages of CZP include rapid reduction of disease activity, low rates of injection-site reaction and may be safe for use in pregnancy. The long-term data strengthen the position of CZP for use either as monotherapy or preferably in combination with disease modifying anti-rheumatic drugs (DMARDs), in moderate-to-severely active RA, comparable to other TNF-is. Notably, prolonged CZP exposure is not associated with increased risk of severe infection compared to general population, contrasting with preliminary analysis of short-term data. Over the next few years, evidence will be available on the use of CZP in combination with methotrexate for remission induction in DMARD-naïve patients, biomarkers and the development and licensing of TNF-i biosimilars. |
| تدمد: | 1744-7682 1471-2598 |
| DOI: | 10.1517/14712598.2014.900043 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b77d33a203f86470a1af6199154d5a2f https://doi.org/10.1517/14712598.2014.900043 |
| رقم الانضمام: | edsair.doi.dedup.....b77d33a203f86470a1af6199154d5a2f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447682 14712598 |
|---|---|
| DOI: | 10.1517/14712598.2014.900043 |